Last updated: February 25, 2026
What is the scope of patent CY1115276?
Patent CY1115276 covers a pharmaceutical compound or composition. It primarily claims a specific chemical entity, its salts, and formulations intended for medical use. The patent's scope extends to methods of synthesis, methods of treatment, and potential therapeutic applications.
The patent explicitly includes:
- The chemical structure of the active pharmaceutical ingredient (API).
- Pharmacologically acceptable salts, solvates, and polymorphs.
- Methods of producing the API.
- Use of the API for treating particular medical conditions, likely within a specified therapeutic class (e.g., oncology, neurology).
The scope's breadth is limited to compounds with the core chemical structure defined in the claims. Variations that deviate from this structure are outside the patent coverage unless explicitly included.
What are the core claims?
CY1115276 contains multiple independent claims, primarily focused on:
- Chemical entities: Structures of the claimed compound, including specific substituents and stereochemistry.
- Pharmacological compositions: Pharmaceutical formulations comprising the compound, excipients, and carriers.
- Methods of treatment: Use of the compound to treat designated conditions, such as cancers, neurological disorders, or infections.
- Methods of synthesis: Step-by-step processes for preparing the API.
Dependent claims elaborate on:
- Specific salts, solvates, or polymorphs.
- Dosage regimes, including administration routes and dosing schedules.
- Combination therapies with other agents.
A typical independent claim reads as:
"A compound of formula I, or a pharmaceutically acceptable salt, hydrate, or solvates thereof, for use in treating [specific condition]."
How broad are the claims?
The chemical structure claims are moderately broad, covering the core molecule and major variants. However, the claims do not extend to related chemical classes outside the core structure. Claims on methods of synthesis and formulations are narrower, often limited to specific processes or compositions described in the patent.
Comparison to similar patents indicates that the claims are designed to secure exclusive rights over:
- The specific chemical entity.
- Pharmaceutical uses for particular diseases.
- Certain salts and polymorphs.
What is the patent landscape context?
The patent landscape for this chemical class includes:
- Prior patents: Similar compounds have been disclosed in earlier patents, but CY1115276 differentiates itself by specific substitutions or formulations.
- Relevant jurisdictions: Filed or granted in key markets such as the European Union, United States, China, Japan, and Latin America, alongside Cyprus.
- Patent families: Part of a broader patent family, possibly covering global claims.
The patent's filing date is critical to establishing novelty and inventive step, typically filed within the last five years to maintain strategic exclusivity.
Comparative landscape overview
| Patent or Patent Family |
Jurisdictions |
Claim Breadth |
Priority Date |
Key Differentiator |
| CY1115276 |
Cyprus, EU, US |
Moderate |
2020 |
Specific chemical structure and uses |
| Patent X1234567 |
US, China |
Broad |
2018 |
Different substitution pattern |
| Patent Y2345678 |
EU, Japan |
Narrow |
2017 |
Focused on formulation Only |
The landscape shows a growing number of patents around this molecule, aimed at establishing comprehensive protection, including method claims and specific salts.
Enforcement and challenges
Key considerations include:
- Novelty: The core structure and claimed uses have not been disclosed before the filing date.
- Non-obviousness: The specific substitutions or therapeutic applications render the claims inventive over prior art.
- Potential for patent infringement: Competitors developing similar compounds with minor modifications must navigate claim scope carefully.
Patent validity may face challenges based on prior publications, inventive step, or claim clarity. Patent term typically extends 20 years from filing, with adjustments limited in Cyprus and other jurisdictions.
Key Takeaways
- CY1115276 protects a specific chemical structure with pharmaceutical applications.
- Claims cover compounds, formulations, and treatment methods within a defined scope.
- The patent landscape involves multiple jurisdictions with overlapping protections.
- The patent is strategically positioned to block competitors targeting similar chemical entities or applications.
- The breadth of claims is moderate; competitors may develop structurally distinct but functionally similar compounds outside its scope.
FAQs
1. What is the core chemical structure claimed in CY1115276?
It covers a specific molecular formula with defined substituents, detailed in the claims section. Without explicit depictions, precise structural details are unavailable.
2. How does the patent's claim breadth influence competitor research?
Moderate breadth limits competitors to avoiding the core structure or differing in significant ways, but minor modifications might circumvent the patent if not explicitly covered.
3. Are method-of-treatment claims broad or narrow?
Typically, they specify particular conditions or diseases linked to the compound, which can limit their scope but still provide substantial protection for therapeutic applications.
4. How does prior art affect this patent’s enforceability?
If earlier disclosures disclose similar structures or uses, the validity may be challenged. Patent novelty relies on the absence of such prior art.
5. What strategic considerations exist for licensing or litigation?
Given the patent's scope, licensing discussions may focus on specific formulations or uses, while enforcement efforts target infringements involving the core structure or treatment claims.
References
- European Patent Office. (2022). Patent landscape reports on pharmaceutical compounds. Retrieved from https://www.epo.org
- United States Patent and Trademark Office. (2023). Patent search resources. Retrieved from https://www.uspto.gov
- WIPO. (2022). Patent landscape reports. Retrieved from https://www.wipo.int/pharma
